anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Futibatinib
Trial phase: Phase 1 | Phase 2
ATC code: L01EN04
SMILES: C=CC(=O)N1CC[C@H](n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Participants with other tumor types who were enrolled prior to the confirmation of the RP2D received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death (maximum exposure: 45.5 months).
Eligibility criteria:
Inclusion Criteria:

Provide written informed consent
Age ≥ 18 years of age
Has histologically or cytologically confirmed, locally advanced or metastatic cancer

The following specific criteria for each study portion

Phase 1 (Dose Escalation):

Patients with any type of solid tumor
Disease progression following standard therapies or intolerant to prior standard therapies

Phase 1 (Dose Expansion)

Have at least one FGF/FGFR aberration
Disease progression following standard therapies or were intolerant to prior standard therapies (including prior FGFR inhibitors).
Have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009) for advanced solid tumors or Response Assessment in Neuro-Oncology criteria (2010) for brain tumors.

Patients with any of the following tumor types

Patients with intrahepatic or extrahepatic CCA harboring FGFR2 gene fusions or other FGFR2 aberrations
Patients with primary CNS tumors
Patients with advanced urothelial carcinoma with FGFR3 fusions or FGFR3 activating mutations
Patients with breast cancer or gastric cancer
Patients with other solid tumor types harboring FGFR gene fusions or activating mutations
Patients with solid tumor types and other FGF/FGFR alterations not listed above

Phase 2

Patients with iCCA and FGFR2 gene rearrangements (incl fusions)
Have been treated with at least one prior systemic gemcitabine and platinum-based chemotherapy
Must have documentation of radiographic progression of disease
No prior FGFR inhibitor
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009)
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Adequate organ function.

Exclusion Criteria:

History and/or current evidence of clinically significant non-tumor related alteration of calcium-phosphorus homeostasis.
History and/or current evidence of clinically significant ectopic mineralization/calcification.
History and/or current evidence of clinically significant retinal disorder
A serious illness or medical condition(s)
Pregnant or breast-feeding female
Intervention: l-Alanyl-l-glutamine
Trial phase: Phase 2
ATC code: B05XB02
SMILES: CC(N)C(=O)NC(CCC(N)=O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Alanyl-glutamine, 44g, taken by mouth daily for 10 days.

Alanyl-glutamine: Alanyl-glutamine, 44g, taken by mouth daily for 10 days
Eligibility criteria:
Inclusion Criteria:

Adult of either gender, 18 years or older, with C. difficile infection (CDI)
Diarrhea associated with C. difficile positive stool assay
Within 48 hours of receiving either metronidazole for mild-moderate disease or vancomycin for severe uncomplicated disease
Admitted in the hospital at the time of enrollment
Ability to provide informed consent
Have an understanding of study procedures
Ability to comply with study procedures for the entire length of the study

Exclusion Criteria:

Hypotension or shock
Megacolon or moderate to severe ileus
Acute abdomen
Severe leukocytosis (WBC > 20,000 cells /µL)
Admission to intensive care unit on enrollment
Inability to tolerate oral medication
Other known etiology of diarrhea (e.g. other enteric pathogen, other intestinal disease)
Inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)
Enrollment in another investigational drug trial
Currently receiving other alternative treatment for CDI (e.g. antibiotics other than metronidazole or vancomycin; probiotics; immunoglobulin therapy; fecal transplant)
Pregnancy
Unavailable for follow-up visits
Life expectancy of < 6 months
Chronic liver disease or in subjects without known liver disease, ALT > 3x normal
Chronic kidney disease or in subjects without known kidney disease, estimated Creatinine clearance of < 30 ml/min, even after rehydration
Intervention: Tranexamic acid
Trial phase: Phase 2 | Phase 3
ATC code: B02AA02
SMILES: NC[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Tranexamic Acid (Cyklokapron) Loading Dose 50mg/kg given over 15 minutes, followed by 5mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.

Tranexamic Acid (Cyklokapron)
Eligibility criteria:
Inclusion Criteria:

Adult patients (ages 18-75) scheduled to undergo long segment (greater than 8 motion segments) posterior spinal fusion with instrumentation (PSF) for adult scoliosis

Exclusion Criteria:

Patients with acquired defective color vision
Subarachnoid hemorrhage
Active intravascular clotting
Hypersensitivity to tranexamic acid or any of the ingredients
Patients who pre-donate autologous blood for intra- or post-operative use (Directed donor units are acceptable)
History of suspected blood disorders or abnormal coagulation laboratory results
Current anticoagulation therapy that cannot be interrupted
History of deep vein thrombosis (DVT)
Impaired renal function or creatinine clearance <60 ml/min
Pregnancy or women who are lactating/breastfeeding
Women on hormonal contraceptives
Intervention: Tranexamic acid
Trial phase: Phase 2 | Phase 3
ATC code: B02AA02
SMILES: NC[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Tranexamic Acid (Cyklokapron) Loading Dose 10mg/kg given over 15 minutes, followed by 1mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.

Tranexamic Acid (Cyklokapron)
Eligibility criteria:
Inclusion Criteria:

Adult patients (ages 18-75) scheduled to undergo long segment (greater than 8 motion segments) posterior spinal fusion with instrumentation (PSF) for adult scoliosis

Exclusion Criteria:

Patients with acquired defective color vision
Subarachnoid hemorrhage
Active intravascular clotting
Hypersensitivity to tranexamic acid or any of the ingredients
Patients who pre-donate autologous blood for intra- or post-operative use (Directed donor units are acceptable)
History of suspected blood disorders or abnormal coagulation laboratory results
Current anticoagulation therapy that cannot be interrupted
History of deep vein thrombosis (DVT)
Impaired renal function or creatinine clearance <60 ml/min
Pregnancy or women who are lactating/breastfeeding
Women on hormonal contraceptives
Intervention: ASPIRIN
Trial phase: Phase 4
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 123
Group description: One aspirin 81 mg capsule 2 times per day

Aspirin
Eligibility criteria:
Inclusion Criteria:

Provision of informed consent prior to any study specific procedures
Female and/or male patients aged 18-90 years
Patients undergoing first-time CABG with at least 1 saphenous vein graft, irrespective of concurrent valve surgery

Exclusion Criteria:

Inability to provide informed consent
Pregnancy or seeking pregnancy
Patients undergoing redo-CABG
Serum creatinine >1.8 mg/dL (need for contrast with CT coronary angiogram)
Hypersensitivity or allergy to aspirin or ticagrelor
Anticipated need for postoperative anticoagulation with coumadin, dabigatran or rivaroxaban (mechanical valve, chronic atrial fibrillation, DVT/PE)
History of gastrointestinal hemorrhage
Active pathological bleeding
History of intracranial hemorrhage
Severe hepatic impairment
Current or anticipated use of strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazadone, ritonavir, and atazanavir)
Intervention: Ticagrelor
Trial phase: Phase 4
ATC code: B01AC24
SMILES: CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 127
Group description: One ticagrelor 90 mg capsule 2 times per day

Ticagrelor
Eligibility criteria:
Inclusion Criteria:

Provision of informed consent prior to any study specific procedures
Female and/or male patients aged 18-90 years
Patients undergoing first-time CABG with at least 1 saphenous vein graft, irrespective of concurrent valve surgery

Exclusion Criteria:

Inability to provide informed consent
Pregnancy or seeking pregnancy
Patients undergoing redo-CABG
Serum creatinine >1.8 mg/dL (need for contrast with CT coronary angiogram)
Hypersensitivity or allergy to aspirin or ticagrelor
Anticipated need for postoperative anticoagulation with coumadin, dabigatran or rivaroxaban (mechanical valve, chronic atrial fibrillation, DVT/PE)
History of gastrointestinal hemorrhage
Active pathological bleeding
History of intracranial hemorrhage
Severe hepatic impairment
Current or anticipated use of strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazadone, ritonavir, and atazanavir)
Intervention: Polidocanol
Trial phase: Phase 4
ATC code: C05BB02
SMILES: CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 43
Group description: An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml.

Polidocanol with Glucose: An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
Eligibility criteria:
Inclusion Criteria:

females
with at least 10 cm from the lateral reticular veins of the leg or thigh of the leg
clinical classification of chronic venous disease C1(mild venous disease),
minimum age of 18 year-old and maximum age 69 year-old
agreement with the study
signing the free and informed consent ( IC)
not use anticoagulant drugs .

Exclusion Criteria:

male
varicose disease in any quantity or location with clinical classification of chronic venous disease different of C1(mild venous disease)
restrict mobility
arterial insufficiency
be allergic to any substance that may be related to the study drugs
any cause of dermatitis on application site
free of comorbidities clinically serious as diabetes mellitus, heart failure, respiratory failure, uncontrolled hypertension with medication, and uncontrolled hypothyroidism
pregnancy
previous deep vein thrombosis (DVT)
family history of DVT
thrombophilia
do not agree with the search terms
Intervention: Brexpiprazole
Trial phase: Phase 3
ATC code: N05AX16
SMILES: O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 64
Group description: Participants were administered brexpiprazole tablets orally QD, starting dose at 1 mg/day for 4 days followed by 2 mg/day for 3 days and 3 mg/day at the week 1 visit and 1, 2, 3, or 4 mg/day from week 2 to week 6.
Eligibility criteria:
Inclusion Criteria:

18 to 65 years of age, inclusive, at the time of informed consent with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I) for Schizophrenia and Psychotic Disorders Studies
Would benefit from hospitalization or continued hospitalization for treatment of a current acute relapse of schizophrenia at trial entry
Are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by all of the following:
Positive and Negative Syndrome Scale (PANSS) Total Score of ≥ 80
Score of ≥ 4 on two or more of the following PANSS items at screening: hallucinatory behavior, unusual thought content, conceptual disorganization, or suspiciousness
Clinical Global Impression - Severity of Illness Scale (CGI-S) score ≥ 4 (moderately ill)

Exclusion Criteria:

Are presenting with a first episode of schizophrenia based on the clinical judgment of the investigator
Have been hospitalized > 21 days for the current acute episode at the time of the baseline visit
Have a current DSM-IV-TR Axis I diagnosis other than schizophrenia, including, but not limited to, schizoaffective disorder, major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, anxiety disorders, delirium, dementia, amnestic, or other cognitive disorders; also borderline, paranoid, histrionic, schizotypal, schizoid, antisocial personality disorders or mental retardation.
Improvement of ≥ 20% in total PANSS score between the screening and baseline assessments.
Intervention: Aripiprazole
Trial phase: Phase 3
ATC code: N05AX12
SMILES: O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Participants were administered aripiprazole tablets orally QD, starting dose at 10 mg/day for 1 week, followed by 15 mg/day at the Week 1 visit and 10, 15, or 20 mg/day from week 2 to week 6.
Eligibility criteria:
Inclusion Criteria:

18 to 65 years of age, inclusive, at the time of informed consent with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I) for Schizophrenia and Psychotic Disorders Studies
Would benefit from hospitalization or continued hospitalization for treatment of a current acute relapse of schizophrenia at trial entry
Are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by all of the following:
Positive and Negative Syndrome Scale (PANSS) Total Score of ≥ 80
Score of ≥ 4 on two or more of the following PANSS items at screening: hallucinatory behavior, unusual thought content, conceptual disorganization, or suspiciousness
Clinical Global Impression - Severity of Illness Scale (CGI-S) score ≥ 4 (moderately ill)

Exclusion Criteria:

Are presenting with a first episode of schizophrenia based on the clinical judgment of the investigator
Have been hospitalized > 21 days for the current acute episode at the time of the baseline visit
Have a current DSM-IV-TR Axis I diagnosis other than schizophrenia, including, but not limited to, schizoaffective disorder, major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, anxiety disorders, delirium, dementia, amnestic, or other cognitive disorders; also borderline, paranoid, histrionic, schizotypal, schizoid, antisocial personality disorders or mental retardation.
Improvement of ≥ 20% in total PANSS score between the screening and baseline assessments.
Intervention: Semaglutide
Trial phase: Phase 3
ATC code: A10BJ06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 128
Group description: Subjects were given 0.25 mg semaglutide once weekly s.c. injection for 4 weeks followed by 0.5 mg semaglutide once weekly s.c. injections for the remaining 26 weeks of the treatment period.
Eligibility criteria:
Inclusion Criteria: - For Japan only: Male or female, age above or equal to 20 years at the time of signing inform consent - Subjects diagnosed with type 2 diabetes and treated with diet and exercise for at least 30 days before screening - HbA1c 7.0 - 10.0 % (53 - 86 mmol/mol) (both inclusive) Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) throughout the trial including the 5 week follow-up period. United Kingdom: Adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository), male sterilisation (where partner is sole partner of subject), or true abstinence (when in line with preferred and usual lifestyle) - Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol - Treatment with any glucose lowering agent(s) in a period of 90 days prior to screening. An exception is short-term treatment (no longer than 7 days in total) with insulin in connection with inter-current illness - History of chronic or idiopathic acute pancreatitis - Screening calcitonin value above or equal to 50 ng/L (pg/mL) - Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) - Impaired renal function defined as eGFR (estimated glomerular filtration rate ) below 30 mL/min/1.73 m^2 per modification of diet in renal disease (MDRD) formula (4 variable version) - Acute coronary or cerebrovascular event within 90 days before randomisation - Heart failure, New York Heart Association class IV
Intervention: Semaglutide
Trial phase: Phase 3
ATC code: A10BJ06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 130
Group description: Subjects were given 0.25 mg semaglutide once weekly s.c. injection for 4 weeks, 0.5 mg semaglutide once weekly s.c. injections for the next 4 weeks followed by 1.0 mg semaglutide once weekly s.c. injections for the remaining 22 weeks of the treatment period.
Eligibility criteria:
Inclusion Criteria: - For Japan only: Male or female, age above or equal to 20 years at the time of signing inform consent - Subjects diagnosed with type 2 diabetes and treated with diet and exercise for at least 30 days before screening - HbA1c 7.0 - 10.0 % (53 - 86 mmol/mol) (both inclusive) Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) throughout the trial including the 5 week follow-up period. United Kingdom: Adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository), male sterilisation (where partner is sole partner of subject), or true abstinence (when in line with preferred and usual lifestyle) - Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol - Treatment with any glucose lowering agent(s) in a period of 90 days prior to screening. An exception is short-term treatment (no longer than 7 days in total) with insulin in connection with inter-current illness - History of chronic or idiopathic acute pancreatitis - Screening calcitonin value above or equal to 50 ng/L (pg/mL) - Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) - Impaired renal function defined as eGFR (estimated glomerular filtration rate ) below 30 mL/min/1.73 m^2 per modification of diet in renal disease (MDRD) formula (4 variable version) - Acute coronary or cerebrovascular event within 90 days before randomisation - Heart failure, New York Heart Association class IV
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the treatment group will receive infusion of 15 cc 0.5% Bupivicaine.

0.5% Bupivicaine: Local anesthetic
Eligibility criteria:
Inclusion Criteria:

Age 18 or older with unilateral or bilateral inguinal herna for laparoscopic repair
American Society of Anesthesiology (ASA) Class I and II

Exclusion Criteria:

Conversion from laparoscopic to open surgery
History of Chronic pain or ongoing treatment for chronic pain
Age less than 18 yrs
Allergy to local anesthetics
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the placebo group will receive the infusion of 15 cc 0.9% Saline.

0.5% Bupivicaine: Local anesthetic
Eligibility criteria:
Inclusion Criteria:

Age 18 or older with unilateral or bilateral inguinal herna for laparoscopic repair
American Society of Anesthesiology (ASA) Class I and II

Exclusion Criteria:

Conversion from laparoscopic to open surgery
History of Chronic pain or ongoing treatment for chronic pain
Age less than 18 yrs
Allergy to local anesthetics